This week Congress will hold an important and timely hearing on compounded drugs. The hearing brings stakeholders together to reflect on a law enacted nearly five years ago in response to serious public health incidents. In 2012, a nationwide fungal meningitis outbreak originating from contaminated injectable compounded sterile drugs sickened over 750 individuals and resulted in the deaths of more than 70.
As government agencies consider solutions to the growing opioid crisis, the Food and Drug Administration (FDA) recently sought public comment about ways to best address this national emergency. USP was pleased to provide our perspective about how public standards might help support the agency’s efforts, and to report on our recent discussions with stakeholders and the standards being considered by USP’s Healthcare Quality Expert Committee.